Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity.
CD2
NK alloreactivity
NK cell
antibody-dependent cell-mediated cytotoxicity
siplizumab
spontaneous cytotoxicity
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
08
2020
accepted:
05
01
2021
entrez:
1
3
2021
pubmed:
2
3
2021
medline:
24
6
2021
Statut:
epublish
Résumé
The glycoprotein CD2 is expressed on T and NK cells and contributes to cell-cell conjugation, agonistic signaling and actin cytoskeleton rearrangement. CD2 has previously been shown to have an important function in natural NK cell cytotoxicity but to be expendable in antibody-mediated cytotoxicity. Siplizumab is a monoclonal anti-CD2 IgG1 antibody that is currently undergoing clinical trials in the field of transplantation. This study investigated the effect of CD2 binding and Fc γ receptor binding by siplizumab (Fc-active) and Fc-silent anti-CD2 monoclonal antibodies in allogeneic mixed lymphocyte reaction and autologous lymphocyte culture. Further, induction of NK cell fratricide and inhibition of natural cytotoxicity as well as antibody-dependent cytotoxicity by these agents were assessed. Blockade of CD2
Identifiants
pubmed: 33643309
doi: 10.3389/fimmu.2021.599526
pmc: PMC7904868
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
CD2 Antigens
0
Receptors, IgG
0
siplizumab
KUW1QG1ZM3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
599526Informations de copyright
Copyright © 2021 Binder, Sellberg, Cvetkovski, Berg, Berglund and Berglund.
Déclaration de conflit d'intérêts
CB, FS, FC, SB, EB and DB are employees of ITB Med AB. SB, EB, and DB own shares in ITB Med AB. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Transplantation. 1999 Nov 27;68(10):1588-96
pubmed: 10589960
J Clin Invest. 2012 Oct;122(10):3769-80
pubmed: 23006327
Am J Transplant. 2011 Jan;11(1):22-33
pubmed: 21070604
J Immunol. 1997 Aug 1;159(3):1200-7
pubmed: 9233614
Nat Immunol. 2020 Oct;21(10):1232-1243
pubmed: 32929275
Blood. 2003 Apr 15;101(8):3052-7
pubmed: 12480696
Arthritis Res Ther. 2013 Jul 11;15(4):216
pubmed: 23856014
J Leukoc Biol. 2008 Dec;84(6):1511-20
pubmed: 18719017
Front Immunol. 2014 Apr 10;5:159
pubmed: 24782864
Adv Immunol. 2014;124:137-70
pubmed: 25175775
J Immunol. 2007 Jun 1;178(11):7442-9
pubmed: 17513795
Am J Transplant. 2016 Mar;16(3):751-7
pubmed: 26690302
Protein Eng Des Sel. 2016 Oct;29(10):457-466
pubmed: 27578889
Eur J Immunol. 2002 Aug;32(8):2188-98
pubmed: 12209631
Sci Rep. 2016 Oct 04;6:34382
pubmed: 27698437
Front Immunol. 2020 Nov 11;11:592553
pubmed: 33262770
Front Immunol. 2017 Sep 13;8:1124
pubmed: 28955340
Clin Exp Immunol. 1996 Mar;103(3):408-13
pubmed: 8608639
PLoS One. 2013;8(3):e60144
pubmed: 23555904
Am J Transplant. 2020 Jan;20(1):88-100
pubmed: 31319439
Immunology. 2010 Dec;131(4):451-8
pubmed: 21039469
Scand J Immunol. 2020 Jan;91(1):e12839
pubmed: 31630416
J Allergy Clin Immunol. 2017 Apr;139(4):1321-1330.e4
pubmed: 27670241
Mol Immunol. 2015 Feb;63(2):456-63
pubmed: 25451975
Mol Immunol. 2004 Aug;41(10):985-1000
pubmed: 15302161
Front Immunol. 2019 Sep 24;10:2279
pubmed: 31616441
Transplantation. 2000 Jun 27;69(12):2622-33
pubmed: 10910286
Front Immunol. 2020 Jun 09;11:1090
pubmed: 32582179
Front Immunol. 2019 Apr 30;10:946
pubmed: 31114585
Nat Commun. 2019 Aug 26;10(1):3841
pubmed: 31451696
Exp Ther Med. 2017 Sep;14(3):2380-2384
pubmed: 28962171
PLoS One. 2012;7(10):e47664
pubmed: 23112830
J Biol Chem. 2015 Feb 27;290(9):5462-9
pubmed: 25568323
Mol Immunol. 2002 Jan;38(8):587-96
pubmed: 11792427
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14151-6
pubmed: 14612578
Protein Cell. 2018 Jan;9(1):63-73
pubmed: 28986820